| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Ro 41-1049 hydrochloride, the hydrochloride salt of Ro 41-1049, is a novel, potent, selective, reversible and orally bioavailable inhibitor of MAO-A (Monoamine oxidase).
| ln Vivo |
Dopamine levels are dose-dependently increased and dopamine metabolite production is inhibited in Sprague-Dawley rats treated with Ro 41-1049 (1-50 mg/kg; i.p.; 3 hours). Pretreatment with Ro 41-1049 (20 mg/kg) reduced the synthesis of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and considerably boosted the generation of dopamine following levodopa delivery (100 mg/kg IP)[2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rat (200-240 g) [2]
Doses: 1 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg or 50 mg/kg Route of Administration: intraperitoneal (ip) injection; 3 hour Experimental Results: Inhibits dopamine metabolite formation and increases dopamine levels in a dose-dependent manner. Pretreatment at a concentration of 20 mg/kg Dramatically increased dopamine formation after levodopa administration while reducing DOPAC and HVA formation. |
| References |
[1]. Cesura AM, et al. Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A. Mol Pharmacol. 1990 Mar;37(3):358-66.
[2]. Brannan T, et al. Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: an in vivo study. J Neural Transm Park Dis Dement Sect. 1994;8(1-2):99-105. |
| Molecular Formula |
C12H13CLFN3OS
|
|---|---|
| Molecular Weight |
301.767523527145
|
| CAS # |
127917-66-2
|
| Related CAS # |
127500-84-9; 127917-66-2 (HCl)
|
| SMILES |
O=C(C1=C(C2=CC=CC(F)=C2)SC=N1)NCCN.[H]Cl
|
| InChi Key |
RRNSPXUFTKJIEZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H12FN3OS.ClH/c13-9-3-1-2-8(6-9)11-10(16-7-18-11)12(17)15-5-4-14;/h1-3,6-7H,4-5,14H2,(H,15,17);1H
|
| Chemical Name |
4-Thiazolecarboxamide, N-(2-aminoethyl)-5-(3-fluorophenyl)-, hydrochloride (1:1)
|
| Synonyms |
RO-41-1049 hydrochloride; RO 41-1049 hydrochloride; RO-41-1049 HCl.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 32 mg/mL (~106.04 mM)
H2O : ~25 mg/mL (~82.84 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (66.28 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3138 mL | 16.5689 mL | 33.1378 mL | |
| 5 mM | 0.6628 mL | 3.3138 mL | 6.6276 mL | |
| 10 mM | 0.3314 mL | 1.6569 mL | 3.3138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA